Concord Drugs

{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "83.87",
    "chg": 2.33,
    "chgp": "2.86%",
    "dir": 1,
    "prev_price": "81.54",
    "mcapval": "110.50 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE858L01010",
    "curr_date": "May 13",
    "curr_time": "",
    "bse_nse_vol": "1.16 k",
    "exc_status": "Active",
    "traded_date": "May 13, 2026",
    "traded_date_str": "2026 05 13",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3989182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordDrugsLtd_mojoScore_3989182.png",
        "date": "2026-05-13 10:11:11",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3972565",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordDrugsLtd_mojoScore_3972565.png",
        "date": "2026-05-02 10:10:38",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts Signal Elevated Price Risk Amidst Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-signal-elevated-price-risk-amidst-strong-returns-3958273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_valuationdot_3958273.png",
        "date": "2026-04-23 08:00:44",
        "description": "Concord Drugs Ltd has seen a marked shift in its valuation parameters, moving from fair to expensive territory, prompting a downgrade in its investment grade. With a price-to-earnings (P/E) ratio soaring to 200.86 and price-to-book value (P/BV) at 3.33, investors are urged to reassess the stock’s price attractiveness amid sector peers and historical benchmarks."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3955792",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_mojoScore_3955792.png",
        "date": "2026-04-21 10:10:33",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-fair-amidst-elevated-price-multiples-3948045",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_valuationdot_3948045.png",
        "date": "2026-04-16 08:00:52",
        "description": "Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating, driven primarily by a steep rise in its price-to-earnings (P/E) ratio and price-to-book value (P/BV). This change comes amid a mixed performance in the pharmaceuticals sector and raises questions about the stock’s price attractiveness relative to its peers and historical benchmarks."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3941407",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_mojoScore_3941407.png",
        "date": "2026-04-10 10:10:57",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3923728",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ConcordDrugsLtd_mojoScore_3923728.png",
        "date": "2026-03-30 10:10:31",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3893195",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ConcordDrugsLtd_mojoScore_3893195.png",
        "date": "2026-03-16 10:10:31",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3852284",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugsLtd_mojoScore_3852284.png",
        "date": "2026-02-24 08:11:12",
        "description": "Concord Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 February 2026. This shift reflects a complex interplay of deteriorating technical indicators, subdued financial performance, and valuation adjustments, despite the company’s long-term market outperformance. Investors should carefully consider these factors amid the stock’s recent 5% decline and evolving market dynamics."
      }
    ],
    "total": 279,
    "sid": "605306",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "06-May-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary <br/> EmailId: csconcorddrugs@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: csconcorddrugs@gmail.com</div> </div> <div> <br/> Date: 06/05/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "10-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>10.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha Nagla <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: csconcorddrugs@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Koni Reddy Seelam <br/> Designation: CFO <br/> EmailId: concorddrugsltd@gmail.com</div> </div> <div> <br/> Date: 10/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
      "datetime": "10-Apr-2026",
      "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Concord Drugs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230TG1995PLC020093</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-20252025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Namratha Nagla</td></tr><tr><td>Designation :-</td><td>Compliance officer and Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>koni Reddy seelam</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 10/04/2026<br/><br/></div>",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Drugs Ltd is Rated Sell

2026-05-13 10:11:11

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-05-02 10:10:38

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Concord Drugs Ltd Valuation Shifts Signal Elevated Price Risk Amidst Strong Returns

2026-04-23 08:00:44

Concord Drugs Ltd has seen a marked shift in its valuation parameters, moving from fair to expensive territory, prompting a downgrade in its investment grade. With a price-to-earnings (P/E) ratio soaring to 200.86 and price-to-book value (P/BV) at 3.33, investors are urged to reassess the stock’s price attractiveness amid sector peers and historical benchmarks.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-04-21 10:10:33

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples

2026-04-16 08:00:52

Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating, driven primarily by a steep rise in its price-to-earnings (P/E) ratio and price-to-book value (P/BV). This change comes amid a mixed performance in the pharmaceuticals sector and raises questions about the stock’s price attractiveness relative to its peers and historical benchmarks.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-04-10 10:10:57

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-03-30 10:10:31

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-03-16 10:10:31

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-02-24 08:11:12

Concord Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 February 2026. This shift reflects a complex interplay of deteriorating technical indicators, subdued financial performance, and valuation adjustments, despite the company’s long-term market outperformance. Investors should carefully consider these factors amid the stock’s recent 5% decline and evolving market dynamics.

Read full news article

View All News